Tuesday, November 17, 2026

DuChemBio's Dementia Diagnostic Drug Revenue Rises 33%... Demand Expected to Grow as Treatments Expand

Input
2026-11-17 08:21:52
Updated
2026-11-17 08:21:52
[Financial News] Sales of Alzheimer's disease diagnostic agents by DuChemBio, a company specializing in radiopharmaceuticals, have been steadily increasing this year. The rise reflects growing demand for amyloid positron emission tomography (PET), a required test before treatment, as prescriptions for the Alzheimer's disease drug Leqembi have expanded in Korea. Expectations for growth in the diagnostic market are also rising ahead of the domestic launch of the follow-up treatment Kisunla.
According to industry sources on the 17th, DuChemBio posted revenue of 11 billion won in the third quarter of this year, up 11.1% from the same period a year earlier. In particular, cumulative sales from the first through the third quarter of Nuraceq and Vizamyl, radiopharmaceuticals used to diagnose Alzheimer's disease, rose 32.7% to 7.1 billion won.
This growth is tied to the expansion of the Alzheimer's disease treatment market. Leqembi (generic name: lecanemab), an anti-amyloid treatment currently prescribed in Korea, requires an amyloid PET scan before administration to determine whether amyloid has accumulated in the brain. As prescriptions for the treatment increase, demand for diagnostic tests rises as well.
DuChemBio supplies Nuraceq and Vizamyl to 120 medical institutions nationwide. Cumulative sales through the third quarter of this year totaled 16,959 doses, up 33.6% from 12,690 doses in the same period last year.
The domestic launch of Eli Lilly and Company's Alzheimer's disease treatment Kisunla (generic name: donanemab) is also seen as an additional growth driver for the diagnostic market. With Kisunla, PET scans can be used not only before treatment but also during treatment to check whether amyloid has been cleared and determine when to end treatment. This means demand for testing could grow both before and after treatment.
DuChemBio is also working to expand production and its supply network to meet rising demand. It currently operates a same-day supply system based on five manufacturing sites nationwide. In May, it signed a business agreement with the Korean Association of Neurologists and is building a cooperative system to connect patients treated at neurology clinics with PET testing facilities. The plan is to expand association-certified partner hospitals into regional testing hubs.
Diagnostic products beyond those for Alzheimer's disease also posted growth. Sales of ProstaSeek, a prostate cancer diagnostic agent that went on sale last December, rose from 300 million won in the first quarter to 500 million won in the third quarter. Third-quarter sales of FP-CIT, a diagnostic agent for Parkinson's disease, increased 9.3% year on year to 1.2 billion won. The company is also investing in production infrastructure. In September, DuChemBio signed a 34.3-billion-won investment agreement with Jeonbuk State, Jeongeup-si and the Jeonbuk R&D Special Zone Headquarters to build a dedicated contract development and manufacturing (CDMO) facility for radiopharmaceuticals in the Jeongeup Advanced Science Industrial Complex. The Jeongeup facility will serve as a same-day supply hub for the Honam and Chungcheong regions. The first-phase facility is targeted to begin commercial operations in the second half of 2029, and the second-phase facility in 2032.

[email protected] Jung Sang-hee Reporter